An oral medication for hair loss has demonstrated success in a late-stage clinical trial, according to Veradermics, a biotechnology startup. The company announced the results on Monday, marking a significant milestone in the development of its treatment for hair regrowth.
Veradermics evaluated the drug, named VDPHL01, using two primary metrics: the average number of new hairs grown per square centimeter of scalp and participant satisfaction with the results. Over a six-month period, men who took the medication—either once or twice daily—experienced a notable increase in hair density. Specifically, they grew between 30 and 33 additional hairs per square centimeter, compared to an average of approximately seven additional hairs in the placebo group.
The trial results also highlighted high levels of satisfaction among participants. Between 79% and 86% of men taking VDPHL01 reported visible improvements in their hair growth. Similarly, clinical trial investigators expressed high satisfaction rates, ranging from 72% to 84%.
Reid Waldman, a dermatologist and the chief executive of Veradermics, praised the trial outcomes. “The results are very encouraging and demonstrate the potential of VDPHL01 as a viable treatment option for hair loss,” Waldman stated. The company plans to continue advancing the drug toward regulatory approval and commercialization.
Related articles
FDA Drug Center Acting Director Tracy Beth Høeg Departs Amid Leadership Changes
WASHINGTON — The acting director of the Food and Drug Administration’s drug center, Tracy Beth Høeg, is leaving the agency, according to three sources...
STAT+ Roundup: New Hires and Promotions in Biotech and Pharma
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others....
U.S. Pressures Germany to Increase Payments for Prescription Drugs Amid Trade Tensions
WASHINGTON — Over a recent breakfast, U.S. officials had a message for the German ambassador: pay more for pharmaceuticals. The meeting, between U.S....
Why Changing Pill Colors and Shapes at 73 Are More Than Just an Annoyance
At the ripe old age of 73, I take six drugs — four prescription and two over-the-counter pills — every day. I keep careful track of them. But recently...
PSA Screening Significantly Lowers Prostate Cancer Death Risk, Cochrane Review Confirms
Prostate-specific antigen (PSA) blood testing is likely to reduce the risk of death from prostate cancer, found a new review published on Thursday by...
Ballmaxxing: The Dangerous Testicle Enhancement Trend You Need to Know About
Experts say that “Ballmaxxing” may lead to permanent damage. Image Credit: Heathline/Paloma Rincon Studio/GettyImages Ballmaxxing is the latest social...
Study Links High Air Pollution to Increased Post-Surgical Complications on Utah’s Wasatch Front
New research on Utah’s Wasatch Front—which occasionally experiences the worst air quality in the nation—has found an association between high air poll...
BeOne Secures FDA Approval for Novel Lymphoma Cell Therapy, Advancing Autoimmune Treatment Pipeline
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Biotech’s cell therapy boo...